HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN
Considerations for Use of TILs versus CAR T-cell Therapies

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

Gene Therapy Trial Doses First Patient With Wet AMD in China

The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.

Phase 2b Myasthenia Gravis RNA CAR-T Trial Doses First Patient

Cartesian Therapeutics’ Descartes-08 will be administered as 6 weekly infusions and does not require preconditioning chemotherapy.

Gerhard Ehninger, MD, on Managing Toxicities With Switchable CARs in AML

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Otoferlin-Related Hearing Loss Gene Therapy Cleared for UK Clinical Trial

Decibel Therapeutics expects the trial for DB-OTO to begin in the first half of 2023.

Around the Helix: Cell and Gene Therapy Company Updates – February 1, 2023

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.